Evidence map›Paper›PMID 31739580›Full record

ReviewJournal of clinical medicine2019

Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors.

Bin Ren, J Bart Rose, Yehe Liu, Renata Jaskular-Sztul, Carlo Contreras, Adam Beck, Herbert Chen

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Obesity Inhibits Angiogenesis Through TWIST1-SLIT2 Signaling.Frontiers in cell and developmental biology · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Bin RenDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-2203-6816
J Bart RoseDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Yehe LiuDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, USA.
Renata Jaskular-SztulDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Carlo ContrerasDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Adam BeckDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Herbert ChenDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.ORCID 0000-0003-2923-6079
University of Alabama at Birmingham · USCase Western Reserve University · US

Funding

University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Epigenetic and Transcriptional Regulation of Angiogenic Regulator CD36 and Transformation of Capillaries into Small ArteriesR01HL136423 · NHLBI · VERSITI WISCONSIN, INC. · PI REN, BIN · 2017 to 2020
$1.6M
NHLBI NIH HHS R01 HL136423NIDDK NIH HHS P30 DK079626NIH HHS HL136423
6 · The paper itself

Abstract

Arteriogenesis supplies oxygen and nutrients in the tumor microenvironment (TME), which may play an important role in tumor growth and metastasis. Pancreatic neuroendocrine tumors (pNETs) are the second most common pancreatic malignancy and are frequently metastatic on presentation. Nearly a third of pNETs secrete bioactive substances causing debilitating symptoms. Current treatment options for metastatic pNETs are limited. Importantly, these tumors are highly vascularized and heterogeneous neoplasms, in which the heterogeneity of vascular endothelial cells (ECs) and de novo arteriogenesis may be critical for their progression. Current anti-angiogenetic targeted treatments have not shown substantial clinical benefits, and they are poorly tolerated. This review article describes EC heterogeneity and heterogeneous tumor-associated ECs (TAECs) in the TME and emphasizes the concept of de novo arteriogenesis in the TME. The authors also emphasize the challenges of current antiangiogenic therapy in pNETs and discuss the potential of tumor arteriogenesis as a novel therapeutic target. Finally, the authors prospect the clinical potential of targeting the FoxO1-CD36-Notch pathway that is associated with both pNET progression and arteriogenesis and provide insights into the clinical implications of targeting plasticity of cancer stem cells (CSCs) and vascular niche, particularly the arteriolar niche within the TME in pNETs, which will also provide insights into other types of cancer, including breast cancer, lung cancer, and malignant melanoma.

Indexed as

angiogenesisarteriogenesiscancer stem cellsCD36FoxO1neuroendocrine tumorNotchprotein kinase Dtransdifferentiation

Identifiers

PMID31739580
PMCPMC6912347
OpenAlexW2985869697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.